Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Diabetes mellitus and obesity have become increasingly prevalent problems worldwide. Unfortunately, with traditionally prescribed glucose-lowering medications most individuals with diagnosed diabetes do not achieve and maintain adequate glycemic control over time; it may be even more challenging to lower blood glucose to an appropriate level without inducing a significant associated weight gain. Exenatide and rimonabant are recently developed agents that have demonstrated benefit in both glucose lowering and reduction of body weight. These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations.
Green
Jennifer B
JB
Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Baker House Room 280, Durham, NC 27710, USA. green094@mc.duke.edu
Feinglos
Mark N
MN
D001067:Appetite Depressants / Q000627:therapeutic use*; D063387:Cannabinoid Receptor Antagonists; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D000077285:Rimonabant; D014688:Venoms / Q000627:therapeutic use*
D001067:Appetite Depressants; D063387:Cannabinoid Receptor Antagonists; D007004:Hypoglycemic Agents; D010455:Peptides; D010880:Piperidines; D011720:Pyrazoles; D014688:Venoms; D000077270:Exenatide; D000077285:Rimonabant